Clovis Oncology Inc. (NASDAQ:CLVS) price is hovering higher on Wednesday, September 15, jumping 2.68% above its previous close.
A look at today’s price movement shows that the recent level at last check reads $4.28, with intraday deals fluctuating between $4.23 and $4.40. The company’s 5Y monthly beta was ticking 1.70. Taking into account the 52-week price action we note that the stock hit a 52-week high of $11.10 and 52-week low of $4.06. The stock subtracted -10.46% on its value in the past month.
Clovis Oncology Inc., which has a market valuation of $511.46 million, is expected to release its quarterly earnings report Nov 03, 2021 – Nov 08, 2021. Analysts tracking CLVS have forecast the quarterly EPS to shrink by -0.49 per share this quarter, while the same analysts predict the annual EPS to hit -$2.22 for the year 2021 and up to -$1.34 for 2022. In this case, analysts estimate an annual EPS growth of 49.30% for the year and 39.60% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $39.95 million, with the likely lows of $37.3 million and highs of $45.18 million. Staying with the analyst view, there is a consensus estimate of $158.08 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -3.90% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CLVS a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 6 analysts have assigned CLVS a recommendation rating as follows: 2 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 1 analyst(s) have tagged the Clovis Oncology Inc. (CLVS) stock as Underweight, with 2 recommending Sell. In general, analysts have rated the stock Underweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CLVS’s price is at present -2.82% off the SMA20 and -9.05% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 41.53, with weekly volatility standing at 4.36%. The indicator jumps to 4.54% when calculated based on the past 30 days. Clovis Oncology Inc. (NASDAQ:CLVS)’s beta value is holding at 1.78, while the average true range (ATR) indicator is currently reading 0.20. Considering analysts have assigned the stock a price target range of $3.00-$10.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $5.90. Based on this estimate, we see that today’s price at last check is roughly 31.66% off the estimated low and -127.79% off the forecast high. Investors will no doubt be excited to see the share price fall to $5.50, which is the median consensus price, and at that level CLVS would be -25.28% from recent price.
Turning out attention to how the Clovis Oncology Inc. stock has performed in comparison to its peers in the industry, here’s what we find: CLVS’s stock is 2.68% on the day and -38.86% in the past 12 months, while Eli Lilly and Company (LLY) traded 1.42% in the latest session and is positioned 56.44% up on its price 12 months ago. Another comparison is with AstraZeneca PLC (AZN) whose stock price is up 0.67% in the current trading session, and has flourished 3.59% over the past year. Also, Johnson & Johnson (JNJ) is currently showing up trend of 0.21% while its price kept floating at 11.09% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.26% in today’s early trading, with the Dow Jones Industrial also seeing a positive session on the day with 0.22%.
An analysis of the Clovis Oncology Inc. (NASDAQ:CLVS) stock in terms of its daily trading volume indicates that the 3-month average is 4.06 million.
Current records show that the company has 108.48M in outstanding shares. The insiders’ percentage holdings are 0.40% of outstanding shares while the percentage share held by institutions stands at 48.80%. But the -10.83% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.